Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Wellcome/Warner-Lambert's Zantac 75 clears FDA advisory committee July 13.

This article was originally published in The Tan Sheet

Executive Summary

ZANTAC 75 RECEIVES UNANIMOUS RECOMMENDATION FOR OTC APPROVAL at a joint meeting of the Nonprescription Drugs and Gastrointestinal Drugs Advisory Committees on July 13. Glaxo Wellcome's Zantac 75 (ranitidine HCl) is expected to be the third H2 antagonist approved by FDA this year, following J&J/Merck's Pepcid AC and SmithKline Beecham's Tagamet HB.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel